Trevi Therapeutics
TRVI
153 hedge funds and large institutions have $627M invested in Trevi Therapeutics in 2025 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 65 increasing their positions, 31 reducing their positions, and 23 closing their positions.
110% more repeat investments, than reductions
Existing positions increased: 65 | Existing positions reduced: 31
109% more call options, than puts
Call options by funds: $7.77M | Put options by funds: $3.73M
70% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 23
13% more capital invested
Capital invested by funds: $554M → $627M (+$72.8M)
12% more funds holding
Funds holding: 137 → 153 (+16)
6.59% more ownership
Funds ownership: 91.16% → 97.75% (+6.6%)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AllianceBernstein
Nashville,
Tennessee
|
+$26.5M |
| 2 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$24.8M |
| 3 |
BlackRock
New York
|
+$18M |
| 4 |
O
OrbiMed
New York
|
+$13.6M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
+$12.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$18.8M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$10.5M |
| 3 |
ABG
Ally Bridge Group
New York
|
-$4.32M |
| 4 |
Millennium Management
New York
|
-$4.14M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.98M |
TRVI Hedge Fund Activity: Q2 2025 in Review
153 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Trevi Therapeutics (TRVI) for Q2 2025, worth a combined $627M — up 13% from $554M a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new TRVI positions and 23 closed out — a net gain of 16 holders — while 65 added to existing stakes and 31 trimmed.
The largest buyer was AllianceBernstein, adding an estimated $26.5M. The largest seller was Armistice Capital, exiting entirely with an estimated $18.8M sold.
- 153 institutional investors held Trevi Therapeutics (TRVI) as of Q2 2025, up from 137 in Q1 2025.
- Funds reported $627M of Trevi Therapeutics stock for Q2 2025, up 13% quarter-over-quarter.
- 39 funds opened new Trevi Therapeutics positions in Q2 2025 and 23 closed out, a net change of +16 holders.
- The largest Trevi Therapeutics buyer in Q2 2025 was AllianceBernstein, an estimated $26.5M added.
- The largest Trevi Therapeutics seller in Q2 2025 was Armistice Capital, an estimated $18.8M sold.
Based on aggregated 13F filings for Q2 2025.